non-small cell lung cancer

Research in Review

Statin Use May Improve Survival in Patients With Lung Cancer

07/11/2016

JCP Editors

Statin use may be associated with improved survival among patients with stage IV non-small cell lung cancer (NSCLC), according to findings from a study published in the journal Lung. Prior studies have shown that...

Statin...

07/11/2016

Journal of Clinical Pathways

New Treatment Improves Response in ALK-Positive NSCLC

06/14/2016

JCP Editors

Patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed while on crizotinib (CRZ) may experience improved response rates when treated with the investigational tyrosine kinase...

...

06/14/2016

Journal of Clinical Pathways

Drug Combination Reduces Adverse Events and Need for Dose Reductions

06/02/2016

JCP Editors

The addition of plinabulin to non-small cell lung cancer (NSCLC) treatment with docetaxel may reduce the frequency of adverse events and help prevent dose reductions due to toxicity, according to an abstract at the...

The...

06/02/2016

Journal of Clinical Pathways

Research in Review

Review of EGFR Mutation-Positive NSCLC Drugs Identifies Optimal Treatments

06/02/2016

JCP Editors

A review of treatments for non-small cell lung cancer (NSCLC) that is epidermal growth factor receptor mutation positive (EGFR M+) has identified which therapies are the most effective at managing disease symptoms...

A...

06/02/2016

Journal of Clinical Pathways

Research in Review

Weight Gain a Sign of Successful Treatment in Patients With NSCLC

05/24/2016

JCP Editors

Weight gain may be an indicator of successful treatment for patients with non-small cell lung cancer (NSCLC), according to findings from a recently published article. Past studies have linked unintentional weigh...

Weight...

05/24/2016

Journal of Clinical Pathways

Research in Review

Novel Biomarker Predicts Treatment Response in NSCLC

05/19/2016

JCP Editors

A study of SMARCA/BRG1 expression in patients with non-small cell lung (NSCLC) cancer has found that it is a significant indicator of prognosis and a novel predictive biomarker for increased sensitivity to...

A...

05/19/2016

Journal of Clinical Pathways

Research Reports

Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations

05/06/2016

Jonathan Graham, BS

Stephanie Earnshaw, PhD

Jonathan Lim, BS, MS, MSc

Rakesh Luthra, MS

Rohit Borker, PhD

Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...

...

05/06/2016

Journal of Clinical Pathways

SBRT for Patients With NSCLC Linked to Higher Rates of Non-Cancer Death

05/04/2016

JCP Editors

Using stereotactic body radiation therapy (SBRT) to treat patients with non-small cell lung cancer (NSCLC) may slightly increase the risk of dying from a cause other than cancer, according to research presented at...

Using...

05/04/2016

Journal of Clinical Pathways

NCCN Announces Changes to Guidelines for NSCLC

04/06/2016

JCP Editors

New guidelines for non-small cell lung cancer (NSCLC) recommend testing for epidermal growth factor receptor (EGRF) mutations as a part of routine care for patients diagnosed with non-small cell lung cancer (NSCLC),...

New...

04/06/2016

Journal of Clinical Pathways

Research in Review

Atezolizumab Safely Improves Survival for Patients Previously Treated for Non-Small Cell Lung Cancer

04/01/2016

JCP Editors

Atezolizumab may be a safe and effective option for patients with non-small cell lung cancer (NSCLC) who have progressed on post-platinum chemotherapy, according to results from a phase 2 randomized controlled...

...

04/01/2016

Journal of Clinical Pathways